Young people in the UK: share your thoughts on the vaccine rolloutWe would like to hear from those in the UK who are under 30 about their thoughts on the vaccine rollout A doctor holding an empty vial of AstraZeneca. Photograph: Ina Fassbender/AFP/Getty Images
The "Motor Vehicles Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
Los Angeles, CA, April 12, 2021 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) ("KNOS" or the "Company"), a product development and production company that has significantly changed the way indoor air is moved, filtered and sterilized today announced that last month it completed an exchange with the Dogecoin Cash Foundation of its entire holdings in First Bitcoin (Crypto: BIT) for 600,000,000 Dogecoin Cash (Crypto: DOG). This enables KNOS to participate in its recently formed DogeSPAC at a greater rate than the 20% already earned as the SPAC's sponsor. "With the growing excitement around Dogecoin Cash, Kronos aggressively accepting Dogecoin as payment, and our popular limited edition air purifier rebranded as AirDOGE, we felt that swapping into Dogecoin Cash was a natural fit," stated company President, Michael Rubinov. Customers can purchase the company’s revolutionary clean air products using U.S. Dollars, Dogecoin, and other cryptos by visiting the Kronos shopping portal: https://www.1800safeair.com About Dogecoin Cash Dogecoin Cash was created as a non-inflationary complement to the original Dogecoin, utilizing several important advancements in crypto since the introduction of DOGE in 2013, including: Proof of Content Instead of the carbon-emitting Proof of Work mining used by coins like Bitcoin and Dogecoin, Dogecoin Cash uses the innovative new Proof of Content mechanism to distribute DOG to the community. Under the Proof of Content system, content creators can earn Dogecoin Cash by sharing links on the social platform Tipestry, where members vote to determine how much crypto each post and comment receives. Rather than encouraging energy consumption, this new system rewards people for creating and sharing content. Proof of Work mining currently uses as much power as some entire countries including Greece and Argentina. According to a recent report published by Bank of America, "We believe ESG-minded [environmental, social, and governance] investors have to pay attention to the enormous environmental costs of Bitcoin." DeFi Designed to operate within the decentralized finance ecosystem, Dogecoin Cash exists on both the Ethereum blockchain as an ERC-20 token, and on Binance Smart Chain in the BEP-20 format. It is currently tradeable on decentralized exchanges including Uniswap on Ethereum and PancakeSwap on Binance Smart Chain. Holders can also stake their Dogecoin Cash via smart contract at stake.dog, store their tokens in a wide selection of Ethereum and Biance Smart Chain wallets, and exchange them for other assets such as non-fungible tokens (NFTs). About Kronos Advanced Technologies, Inc. The Company was initially founded in 2002 and funded by the U.S. military to develop electrostatic air movers. Eventually, the Company moved into the consumer air purification business. It began operations as a product development company that invented and significantly changed the way air is moved, filtered, and sterilized. Historically, Kronos has focused on developing, marketing, and selling the Company's proprietary air movement and purification technology. Serving the Indoor Air Quality (IAQ) market, Kronos technology uses state-of-the-art high voltage patented processes without the use of traditional porous HEPA filters. Kronos-based products move air silently, filter, sterilize, and purify the air while dramatically reducing energy consumption to half of a 60-watt light bulb. Kronos devices can be variable in shape or size and, therefore, have the potential to be scaled-down for air purification in cars or scaled-up in size for industrial and hazardous gas destruction. The technology is currently being implemented in multiple standalone products for businesses, homes, and vehicles of all types -to move, sterilize and filter air, including removing allergens down to 14.6 nanometers, passing through our patented technology -replacing expensive outdated passive HEPA and other filtration type systems. There are broad ranges of additional markets for standalone and embedded Kronos CORE technology-based devices. Examples of immediately addressable markets include schools, universities, healthcare facilities, operating rooms, manufacturing clean rooms, and the cabins of automobiles and commercial aircraft. Kronos is the first publicly traded company that accepts DOGE coin as a form of payment for its products, as well as other crypto currencies. Recently, the Company filed for a provisional patent involving an innovative protective face mask with antimicrobial and anti-cellphone radiation protection features. The Company is planning to file additional patents to improve its existing technology as well as enter into new market segments but will continue to market air purifiers and other consumer products. The Company is an exclusive distributor and licensee of the latest generation of air purifiers based on the Company's CORE technologies. The Company markets its products as Airdog® and KRONOS® brands. All Kronos products come with Kronos Promise ™ -Your Satisfaction is Guaranteed! Company offices are located in Los Angeles, California. Shopping portal: https://www.1800safeair.com Follow KNOS on Twitter: https://twitter.com/kronosati Follow KNOS on Facebook: https://www.facebook.com/kronosati Follow KNOS on Instagram: https://www.instagram.com/kronos_ati/ Follow KNOS on Youtube: https://www.youtube.com/channel/UCdtrQDt1R26Ulh8v-S-EpJg Follow KNOS on Reddit: https://www.reddit.com/user/Kronos_ATI Follow KNOS on LinkedIn: https://www.linkedin.com/company/kronos-advanced-techngologies-inc Contact us via firstname.lastname@example.org or visit https://www.kronosati.co or https://www.1800SafeAIR.com Disclaimer This news release does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Kronos Advanced Technologies Inc or any other third party regardless of whether such security, product or service is referenced in this press release. Furthermore, nothing in this press release is intended to provide tax, legal, or investment advice and nothing in it should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction. Kronos Advanced Technologies does not represent that the securities, products, or services discussed in this press release are suitable for any particular investor. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your business advisor, attorney, and/or tax and accounting advisor regarding your specific business, legal or tax situation. Social Media Disclaimer and Forward-Looking Statements. Kronos Advanced Technologies investors and others should note that we announce material information to the public about the Company through various means, including our website (https://www.kronosati.co/investors), through press releases, OTCmarkets filings, public conference calls, via our corporate Social Media accounts, listed above. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time. Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the OTC Markets at OTCMarkets.com. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. SOURCE: KRONOS ADVANCED TECHNOLOGIES, Inc Phone inquiries: 1-800-SAFE-AIR (option #4)
Greensill scandal: government orders inquiry into Cameron lobbyingIndependent investigation launched into former PM’s lobbying for now-collapsed firm David Cameron has come under pressure from Labour to answer questions from MPs. Photograph: Matt Dunham/AP
An investigation by the global chemical weapons watchdog found “reasonable grounds to believe” that a Syrian air force military helicopter dropped a chlorine cylinder on a Syrian town in 2018, sickening 12 people, the Organization for the Prohibition of Chemical Weapons said Monday. It is the second time that the OPCW's Investigation and Identification Team has concluded that Syrian government armed forces likely were responsible for a gas attack.
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Aggreko plc(GB00BK1PTB77)(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 9 April 2021(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” N/A If YES, specify which: 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 4 329/395 p Ordinary Shares Interests Short positions Number % Number %(1) Relevant securities owned and/or controlled: 10,597,211* 4.14% (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 10,597,211 4.14% *Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 333,629 shares. All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unitOrdinary Shares Sale 30,237 GBP 8.7391 (b) Cash-settled derivative transactions Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 12 April 2021 Contact name: Thomas HoneTelephone number: 020 3033 3419 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at email@example.com. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Dublin, April 12, 2021 (GLOBE NEWSWIRE) -- The "Global Medical Writing Market (2020-2025) by Type, Application, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Medical Writing Market is estimated to be USD 3.36 Bn in 2020 and is expected to reach USD 5.95 Bn by 2025, growing at a CAGR of 12.1%.Market DynamicsKey factors such as growth in medical sciences have compelled a need for articulating clear, concise information on complex topics in the pharmaceutical and related life sciences sector. This is prominently driving the growth of the medical writing market. Moreover, with the rising expiries of patents and additional clinical trial processes, there is a constant need of drafting regulatory documents. This has led to a demand in medical writing. Further, the growing partnerships and collaborations in this domain are likely to support the market growth.However, the shortage of skilled medical writers along with less cognizance given to the medical writer for their respective contribution is likely to hamper the growth of the market. Market Segmentation By Type, the market is classified as regulatory writing, scientific writing, clinical writing, and others. Amongst all, the regulatory writing is estimated to hold the highest market share.By Application, the market is classified as medical journalism, medical education, and medico marketing writing. Amongst all, the medical journalism segment is estimated to hold the highest market share.By End User, the market is classified as biotechnology and pharmaceutical companies, and contract research organizations (CROs). Amongst the two, the contract research organizations CROs are estimated to hold the highest market share.By Geography, North America is projected to lead the market. Recent Developments1. Cactus Communications has launched R (researcher.life) which is an integrated ecosystem of tools for academic researchers. The tools shall help the researchers to conduct literature search faster and more intelligently - 4th June 20202. Covance Drug development business has launched a laboratory solution within the Functional Service provider (FSP) Offering to enhance its capabilities in the areas of clinical operations, statistical programming, medical writing, and pharmacovigilance services - 9th September 2019Company ProfilesSome of the companies covered in this report are PAREXEL International Corporation, Trilogy Writing & Consultancy GmBH, Freyr Solutions, and CACTUS Communications.Competitive QuadrantThe report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Why buy this report? The report offers a comprehensive evaluation of the Global Medical Writing Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.The report also contains the competitive analysis using a Competitive Quadrant, the analyst's Proprietary competitive positioning tool. Key Topics Covered: 1 Report Description1.1 Study Objectives 1.2 Market Definition1.3 Currency1.4 Years Considered1.5 Language1.6 Key Shareholders2 Research Methodology2.1 Research Process2.2 Data Collection and Validation220.127.116.11 Secondary Research18.104.22.168 Primary Research2.3 Market Size Estimation2.4 Assumptions of the Study2.5 Limitations of the Study3 Executive Summary4 Market Overview4.1 Introduction 4.2 Market Dynamics4.2.1 Drivers22.214.171.124 Rapid growth in the medical sciences126.96.36.199 Increasing demand for outsourcing of medical writing capabilities 188.8.131.52 Growth in drafting trial regulation and patent registration documents184.108.40.206 Partnerships and collaborations between market players4.2.2 Restraints220.127.116.11 Shortage of skilled medical writers18.104.22.168 Lack of standardized guidance concerning acknowledgment for the medical writer's specific contributions4.2.3 Opportunities22.214.171.124 Role of new technologies in medical writing126.96.36.199 Increasing dependence upon the internet and digital communications188.8.131.52 Growth in medical device regulations4.2.4 Challenges184.108.40.206 Lack of quality evaluation instruments220.127.116.11 Challenges involved in regulatory medical writing4.3 Trends5 Market Analysis5.1 Porter's Five Forces Analysis5.2 Impact of COVID-195.3 Ansoff Matrix Analysis6 Global Medical Writing Market, By Type6.1 Introduction6.2 Clinical Writing6.3 Regulatory Writing6.4 Scientific Writing6.5 Others7 Global Medical Writing Market, By Application7.1 Introduction7.2 Medical Journalism7.3 Medical Education7.4 Medico Marketing7.5 Others8 Global Medical Writing Market, By End User8.1 Introduction8.2 Pharmaceutical and Biotechnology Companies8.3 Contract Research Organizations (CROs)8.4 Others9 Global Medical Writing Market, By Geography9.1 Introduction9.2 North America18.104.22.168 US22.214.171.124 Canada126.96.36.199 Mexico9.3 South America188.8.131.52 Brazil184.108.40.206 Argentina9.4 Europe220.127.116.11 UK18.104.22.168 France22.214.171.124 Germany126.96.36.199 Italy188.8.131.52 Spain184.108.40.206 Rest of Europe9.5 Asia-Pacific220.127.116.11 China18.104.22.168 Japan22.214.171.124 India126.96.36.199 Indonesia188.8.131.52 Malaysia184.108.40.206 South Korea220.127.116.11 Australia18.104.22.168 Russia22.214.171.124 Rest of APAC9.6 Rest of the World126.96.36.199 Qatar188.8.131.52 Saudi Arabia184.108.40.206 South Africa220.127.116.11 United Arab Emirates18.104.22.168 Latin America10 Competitive Landscape10.1 IGR Competitive Quadrant10.2 Market Share Analysis10.3 Competitive Scenario10.3.1.1 Mergers & Acquisitions10.3.1.2 Agreement, Collaborations, & Partnerships10.3.1.3 New Product Launches & Enhancements10.3.1.4 Investments & Fundings11 Company Profiles11.1 IQVIA Holdings Inc11.2 Parexel International Corporation (Pamplona Capital)11.3 Trilogy Writing & Consulting11.4 Covance11.5 OMICS International11.6 Freyr Solutions11.7 Cactus Communications11.8 Certara (EQT)11.9 InClin Inc11.10 SIRO Clinpharm Private Limited11.11 Synchrogenix (Certara)11.12 Quanticate11.13 Icon Plc11.14 Cardinal Health11.15 InfocusRx 11.16 MakroCare 11.17 Intertek Group plc11.18 Clinexa Life Sciences Pvt11.19 Syneos Health11.20 UDG Healthcare Plc 11.21 Indegene11.22 Nucleus Global (Huntsworth)12 Appendix12.1 QuestionnaireFor more information about this report visit https://www.researchandmarkets.com/r/evalll CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
SEOUL, South Korea -- Health officials in South Korea say Maryland-based Novavax has agreed to a licensing arrangement that will allow a South Korean biotech firm to produce its coronavirus vaccines for later this year. Kwon Deok-cheol, South Korea’s health minister, said Monday that SK Bioscience plans to produce 20 million Novavax shots through September, all of which will be used locally. Production could start as early as June. Food and Drug Safety Minister Kim Gang-lip, who joined Kwon in a news conference, said Novavax’s vaccines are currently being reviewed by regulators in Europe and Britain, but didn’t speculate on when the shots would be approved in major countries. SK Bioscience is already producing vaccines developed by AstraZeneca at its manufacturing facility in Andong. South Korea has mainly relied on these shots since it launched its mass immunization campaign in February, but there are fears over possible shortages as officials wrestle with a slower vaccine rollout than many other developed economies. While South Korea hopes to get 150 million doses of coronavirus vaccines this year through bilateral deals with pharmaceutical companies and the WHO-backed COVAX program, it has got just over 3 million doses so far. A little over 1.15 million people have received their first doses as of Monday. Officials have so far maintained their goal of vaccinating 70% of the country’s 51 million people before the start of the new influenza season around November. ___ THE VIRUS OUTBREAK: — Muslims are navigating coronavirus regulations for their second Ramadan in the shadow of the pandemic — China's top disease control official said current vaccines offer low protection, mixing them is among strategies being considered to boost effectiveness — Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine ___ HERE’S WHAT ELSE IS HAPPENING: MADRID — A Spanish pharmaceutical company says it’s setting up a new production line that would produce millions of Moderna’s coronavirus vaccine doses on European Union soil later this year. Rovi’s existing facility in southern Spain’s Granada will receive an undisclosed investment to produce the active ingredient of Moderna’s jab, the company announced Monday in a press release. The expected output will be up to 100 million vaccine doses per year starting in the third quarter of 2021, Rovi said, adding that the production will be destined to markets outside the United States. The facility will be the first of its kind in the EU, adding to the production facilities that the Swiss biotech company Lonza has been operating there. Rovi had until now operated production lines to fill vials with Moderna’s COVID-19 vaccine, but the active component had to be imported into the country. ___ LONDON — British Prime Minister Boris Johnson has urged people to “behave responsibly” as shops, gyms, hairdressers, restaurant patios and beer gardens reopen after months of lockdown. Monday sees the easing of restrictions that have been in place in England since early January to suppress a surge in coronavirus infections linked to a more transmissible new variant of the virus. Helen Dickinson, chief executive of the British Retail Consortium, said businesses were “excited and desperate” to welcome customers back. At a hairdresser in Birmingham, customer Amy Smith said she was thrilled to be getting a trim at last. “It’s great to be here, I’ve been going with this weird little topknot for a few months now,” she said. “I’m going to go to a beer garden experience later, so it’s going to be good.” Many people were planning outdoor meals and drinks, despite unseasonably cold weather that brought snow to London and many other areas. Scotland, Wales and Northern Ireland — are following their own, broadly similar plans to ease lockdown. Britain has had Europe’s worst coronavirus outbreak, with more than 127,000 confirmed deaths. ___ MANILA, Philippines — The hard-hit Philippine capital and four nearby provinces have been placed under a lighter coronavirus lockdown to avoid further damage to an already battered economy despite a continuing surge in infections and deaths. Presidential spokesman Harry Roque said Metropolitan Manila and the provinces of Bulacan, Cavite, Laguna and Rizal, a region of more than 25 million people, would remain under lighter restrictions up to the end of April after a two-week hard lockdown. An 11-hour night curfew has been shortened to nine hours in the Manila metropolis. Most residents, except for workers in authorized businesses and medical and government law and order personnel will have to remain at home from Monday except for urgent errands like grocery runs and medical emergencies. Essential businesses will remain open, including hospitals, supermarkets, convenience stores and banks, but amusement parks, movie houses, cockfighting arenas, fitness gyms and beauty salons will remain shut. “Our emerging strategy is to increase our bed capacities instead of closing the economy,” said Roque, who spoke in a televised news briefing from a Manila hospital after contracting COVID-19 like many Cabinet members. The government has struggled to open more isolation and treatment centres after many hospitals were overwhelmed starting in March by the worst surge in coronavirus infections. More than 1,000 additional beds could now be used, many of them in the government-run National Center for Mental Health, officials said. The Philippines has long been a Southeast Asian coronavirus hotspot, with about 865,000 confirmed infections and nearly 15,000 deaths. ___ GAZA CITY, Gaza Strip — The Gaza Strip has recorded the highest daily deaths since the coronavirus broke out in the Palestinian enclave. The Health Ministry reported Monday that 17 Palestinians have died from COVID-19, bringing the death toll to 694. Gaza is under an Israeli-Egyptian blockade and its Hamas rulers had managed to keep it relatively free of the virus by imposing obligatory quarantine on the few dozens returnees who cross in via Israel or Egypt. But in August, the virus escaped the walls of the isolation centres and spread rapidly. After a significant decrease of infections in February, Hamas removed all precautionary measures and cases resurged. The vaccination rollout is limited. The territory of 2 million people has received vaccines for only 40,000 people, including a shipment via the global COVAX program. ___ WELLINGTON, New Zealand — New Zealand is requiring that all border workers be vaccinated against the coronavirus by the end of the month. Prime Minister Jacinda Ardern said Monday that beginning immediately, employers would need to consider alternative options for any of their employees who haven’t been vaccinated. That could mean those workers are redeployed to roles away from the border or fired. Ardern had previously set April as a deadline for vaccinating frontline workers but on Monday talked about it in stronger terms after three workers at a quarantine facility caught the virus. New Zealand has stamped out the spread of the virus within the community, so returning travellers who may have caught COVID-19 abroad are considered the biggest vulnerability. Ardern said 86% of workers at quarantine facilities have already been vaccinated, although that group only represents a small proportion of all border workers. ___ SEOUL, South Korea — The new mayor of South Korea’s capital demanded swift approval of coronavirus self-testing kits, saying that his city urgently needs more tools to fight the pandemic and keep struggling businesses open. Oh Se-hoon spoke Monday as Seoul and nearby metropolitan towns shut down hostess bars, night clubs and other high-risk entertainment venues to slow transmissions. Similar businesses were also shut down in the southern port city of Busan. The Korea Disease Control and Prevention Agency said 350 of the country’s 587 new cases were from the greater Seoul area. The conservative Oh took office upon winning a byelection last week. He used a news conference to criticize the national liberal government’s anti-virus campaign, which he said was failing to slow infections while also hurting businesses and livelihoods. He said self-testing kits could be sold at pharmacies or supermarkets and produce results within 30 minutes, which would allow businesses more freedom to operate safely. Kwon Jun-wook, director of South Korea’s National Health Institute, said earlier this month that authorities are reviewing whether to approve rapid home tests as they explore ways to cast a wider net to detect virus carriers with no or mild symptoms. But the review has proceeded slowly with some experts saying such tests would do more harm than good because they are less accurate than standard laboratory tests. ___ TOKYO — Tokyo has adopted tougher measures against the coronavirus as it struggles to curb the rapid spread of a more contagious variant ahead of the Olympics in a country where less than 1% of people have been vaccinated. Japan expanded its vaccination drive Monday to older residents, with the first shots being given in about 120 selected places around the country. The tougher COVID-19 rules allow Tokyo’s governor to mandate shorter opening hours for bars and restaurants, punish violators and compensate those who comply. Tokyo Gov. Yuriko Koike urged residents to be cautious while vaccinations are in an early stage. “We are still unarmed as we fight against the resurgence of the infections," she said. The Associated Press
Boris Johnson has ordered an independent review into Greensill Capital following the David Cameron lobbying controversy. Top lawyer Nigel Boardman will lead the investigation into the now-collapsed finance firm's activities in government and the role its founder, Lex Greensill, played. The Whitehall review will look at how government contracts were secured by Greensill as well as the actions of Mr Cameron.
Avetta Announces Two Executive Appointments: Tom McNamara as COO, and Jeff Byal as CFO
Forecasts by Product Type Anaesthesia Devices (Anaesthesia Machines – Anaesthesia Delivery Machines, Anaesthesia Ventilators, Anaesthesia Monitors, Anaesthesia Disposables – Anaesthesia Masks, Anaesthesia Accessories), Respiratory Devices (Equipment – Humidifiers, Nebulizers, Oxygen Concentrators, Positive Airway Pressure Devices, Reusable Resuscitators, Ventilators, Respiratory Inhalers, Respiratory Disposables – Disposable Oxygen Masks, Resuscitators, Tracheostomy Tubes, Nasal Cannula, Respiratory Measurement Devices – Pulse Oximeters, Capnographs, Spirometers, Peak Flow Meters).New York, April 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anaesthesia & Respiratory Devices Market Report 2020-2030" - https://www.reportlinker.com/p06058457/?utm_source=GNW PLUS, Profiles of Leading Anaesthesia & Respiratory Devices Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery ScenariosAnesthesia and Respiratory Devices Market – shows you the latest trends & dynamics, opportunities, and competitive analysis. Read on to exploit the impending revenue pockets emerging in this sector along with detailed COVID-19 recovery scenarios. Our 619-page report provides 351 tables and charts/graphs. Read on to learn the most lucrative segments in the industry and the future market prospects. Our new study lets you evaluate forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Anesthesia and Respiratory Devices Market. See how to exploit opportunities. COVID-19 Impact & Recovery Analysis on the Market The coronavirus pandemic has had an unbelievable impact on the global economic system and on human beings’ daily lives. The impact on the healthcare sector has also been adversely affected and a huge burden is being created on healthcare sectors across the globe that are already pinched. People with respiratory diseases are at higher risk because the coronavirus significantly affects or damages the respiratory system and reduces the body’s oxygen demand. Because of this, with the fastest growth rate, the respiratory device industry gained importance and grew. The demand for respiratory devices has also increased with the increase in the number of COVID-19 patients. The COVID-19 pandemic has increased the worldwide demand for the supply of many different medical devices, especially ventilators and other devices for vital signs. As such, some devices may need to be repurposed to treat seriously ill patients in certain scenarios. For instance, transport ventilators and anaesthetic devices may need to be configured to provide patients with longer-term ventilation. UNIQUE COVID-19 VARIATIONS– only available in this this report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 affects the economy. Which Factors are Fueling Anesthesia and Respiratory Devices Industry Growth? • Rise in geriatric population • Rising awareness for respiratory diseases • Innovations in anesthesia and respiratory devices Which Factors are Restraining Growth? • Unfavorable reimbursement policies • Lack of patient adherence in respiratory diseases • Stringent regulations What are Market Opportunities? • Investment for respiratory diseases • Increased ventilator production • Surge in demand for respiratory devices for home care settings • Rise in number of surgeries that requires anesthesia Forecasts to 2030 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Brazil, Mexico, and rest of Latin America markets are studied as the major markets under Latin America region. A multitude of developing countries make up Latin America. Nearly 600 million people are undergoing demographic shifts, in which rapid population growth is combined with a gradual ageing of the people. For general and respiratory health, this part of the globe presents great challenges. There are substantial or even higher rates of chronic respiratory illnesses or exposure to risk in most countries. Respiratory devices segment dominated the Latin America anesthesia and respiratory devices market by product type and is projected to witness CAGR of 6.7% during the first half of the forecast period i.e. 2020 to 2025. The analyst anticipates that Anesthesia devices segment will witness fastest growth rate of 7.8%during the forecast period i.e. 2020 to 2030. Report Scope Global anesthesia and respiratory devices market 2020-2030 is segmented on the basis of product and geography. Anesthesia and Respiratory Devices Market: By Product Type • Anesthesia Devices – Anesthesia Machines: – Anesthesia Delivery Machines – Anesthesia Ventilators – Anesthesia Monitors – Anesthesia Disposables: – Anesthesia Masks – Anesthesia Accessories • Respiratory Devices – Equipment: – Humidifiers – Nebulizers – Oxygen Concentrators – Positive Airway Pressure Devices – Reusable Resuscitators – Ventilators – Respiratory Inhalers – Respiratory Disposables: – Disposable Oxygen Masks – Resuscitators – Tracheostomy Tubes – Nasal Cannula – Respiratory Measurement Devices: – Pulse Oximeters – Capnographs – Spirometers – Peak Flow Meters In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 15 leading national markets: • North America – U.S. – Canada • Europe – Germany – France – UK – Italy – Spain – Rest of Europe • Asia Pacific – China – Japan – India – Australia – Rest of Asia Pacific • Latin America – Brazil – Mexico – Rest of Latin America • Middle East & Africa – GCC – South Africa – Rest of Middle East & Africa The report also includes profiles and for some of the leading companies in the anesthesia and respiratory devices market, with a focus on this segment of these companies’ operations. Leading companies and the potential for market growth Overall world revenue for Anesthesia and Respiratory Devices Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. COVID-19 Impact on Production of Critical Care Products The companies are ramping up the production of vital health technology products such as hospital ventilators in response to COVID-19 pandemic. For instance, in March 2020, Philips announced to increase the production of hospital ventilators for the treatment of patients with the new coronavirus disease (COVID-19). It is also mobilizing its supplier network to increase production in this extraordinary circumstance. Likewise, in April 2020, Medtronic ramped up the production of ventilators amid COVID-19 pandemic. The company had plans to manufacture 25,000 ventilators across all platforms in six months period. How the Anesthesia and Respiratory Devices Market report helps you In summary, our 610+ page report provides you with the following knowledge: • Revenue forecasts to 2030 for Anesthesia and Respiratory Devices Market, with forecasts for Product Type, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues. Respiratory devices segment accounts for the major share of the global anesthesia and respiratory devices market in 2019 while anesthesia devices segment is expected to be the fastest growing marking during the forecast period. • Revenue forecasts to 2030 for 5 regional and 16 key national markets – See forecasts for the anesthesia and respiratory devices market in North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies. There will be growth in both established and in developing markets. Our analyses show that the U.S. would continue dominating the global anesthesia and respiratory devices market while India is poised to grow at a double digit CAGR during the forecast period, 2020 to 2030. • Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Anesthesia and Respiratory Devices Market. The anesthesia and respiratory devices market is relatively concentrated with top ten players accounting for 57% share of the total market in 2019. Some of the company’s profiled in this report include: – ResMed Inc. – Medtronic plc – Vyaire Medical Inc. – Masimo Corporation – Invacare Corporation – Hamilton Medical AG – Drägerwerk AG & Co. KGaA – Nihon Kohden Corporation – Omron Healthcare, Inc. – Smiths Medical – Royal Philips – General Electric Company Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Anesthesia and Respiratory Devices Market and leading companies. You will find data, trends and predictions.Read the full report: https://www.reportlinker.com/p06058457/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Mi 11X Pro will come with a Snapdragon 888 chipset, 108 MP cameras and 33W fast charging.
The Briton, back with Deceuninck-Quick Step six years after leaving the Belgian outfit, outsprinted Belgian Jasper Philipsen to raise his arms in celebration for the first time since winning the third stage of the Dubai Tour in February, 2018. The 35-year-old, who was pondering retirement last season, had joined Dimension Data in 2016 before spending a season at Bahrain-McLaren. Cavendish, who has won 30 stages on the Tour de France and is considered one of the best sprinters in the event's history, also won the 2011 world championships' road race.
Currencies in emerging markets recovered from initial losses, but traded flat on Monday as focus turned to U.S. inflation data due later in the week, while investors pulled out of equities ahead of the corporate earnings season. The MSCI's index of emerging market currencies was muted after falling as much as 0.2%, with the U.S. dollar and Treasury yields retreating as investors awaited inflation data due on Tuesday. The lira traded flat after leading early losses across Europe, the Middle East and Africa (EMEA).
U.S. laboratory products supplier Avantor said on Monday it had agreed to buy German peer Ritter GmbH for 890 million euros ($1.1 billion) in cash. Its family owners worked with Goldman Sachs to scout the market for potential partners to finance its global expansion, people familiar with the matter had said in February. Avantor said the transaction comes in the wake of 40 completed M&A deals, in which it deployed more than $8 billion in capital and generated well over $350 million in EBITDA synergies.
Mastercard unveils a new Carbon Calculator tool for banks globally, as consumer passion for the environment grows, according to a new study.
EDISON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced booked orders from key customers, including Hecate Energy, Azure Power and ZGlobal Inc., to meet increased demand for energy storage in critical markets such as Texas, California and India. The Hecate project in Texas is the first booked order as part of the broad-ranging agreement to provide over 1 GWh of energy storage projects to Hecate Energy (“Hecate”), which Eos announced in November 2020. Hecate is a leading global developer, owner and operator of solar, natural gas, wind, and energy-storage projects, with 2.1 GW contracted and a pipeline of 12+ GW. Given recent grid challenges in Texas resulting from winter storms, energy storage is more important than ever to ensure a reliable, resilient grid. Eos clean energy solutions provide value to grid operations by integrating renewable electricity and providing this much needed grid support. This project, and the broader arrangement with Hecate, are aimed to address this specific need in many utilities across Texas. The Azure project is part of a large solar development in India where Eos energy storage solutions will be installed to provide solar shifting. Azure Power (NYSE: AZRE) is a leading independent solar power producer with a pan-India portfolio of 6.9 GWh as of February 28, 2021. India’s renewable market has seen dramatic growth over the past few years, and storage is starting its upswing, particularly as independent power producers (“IPPs”), such as Azure Power, commit to using only renewable-generated electricity in the nation’s Round-the-Clock Auctions. Eos’s success in India is driven by its earlier deployment of energy storage systems with a leading IPP to support solar shifting in this critical market, which demonstrated the safety and resilience of Eos’s technology in harsh environments, including temperatures as high as 45°C. The ZGlobal project in California is paired with a solar project and represents a new long-term relationship for the Company. ZGlobal Inc. is a power engineering consultancy firm staffed by veterans of the California Independent System Operator (“CAISO”) and various California utilities. “Texas and California represent key areas of growth for Eos in the U.S., while India presents great potential for our global expansion plans. We are pleased to secure orders from marquee customers in all of these markets, which we believe validates Eos’s technology solution with top tier mainstream customers to address long duration use cases such as renewable shifting,” said Balki Iyer, Chief Commercial Officer of Eos. “We continue to see strong sales momentum as the benefits of our technology, including the low cost of ownership, minimal carbon footprint and resilient supply chain, continue to resonate in the market as customers recognize that storage is crucial to saving energy and redefining the grid. With this announcement, Eos’s orders backlog has grown to approximately $30 million, which includes more than 20 orders totaling approximately 107 MWh over the past six months. In addition, the Company strengthened its pipeline to more than $3.5 billion with expected delivery over the next four years.” The Eos Znyth® technology can be used for front-of-meter grid installations and behind-the-meter industrial applications, among other use cases. The zinc-powered batteries can be deployed as both standalone storage and paired with renewables on the electric grid, in addition to being used in commercial & industrial facilities. About Eos Eos Energy Enterprises, Inc. is accelerating the shift to clean energy with positively ingenious solutions that transform how the world stores power. Our breakthrough Znyth® aqueous zinc battery was designed to overcome the limitations of conventional lithium-ion technology. Safe, scalable, efficient, sustainable — and manufactured in the U.S. — it's the core of our innovative systems that today provide utility, industrial, and commercial customers with a proven, reliable energy storage alternative. Eos was founded in 2008 and is headquartered in Edison, New Jersey. For more information about Eos (NASDAQ: EOSE), visit eose.com. Forward-Looking StatementsThis press release includes certain statements that may constitute "forward-looking statements" for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: the future financial performance of Eos; Eos’s plans for expansion and acquisitions; and changes in Eos's strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the parties' views as of any subsequent date, and Eos does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Eos; (2) the ability to maintain the listing of Eos’s shares of common stock on NASDAQ; (3) the ability of Eos’s business to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (4) changes in applicable laws or regulations; (5) the possibility that Eos may be adversely affected by other economic, business, and/or competitive factors; and (6) other risks and uncertainties indicated from time to time in the Prospectus included as part of the Registration Statement on Form S-1/A filed by Eos with the Securities and Exchange Commission (“SEC”) on January 13, 2021, Registration No.333-251243, including those under the heading "Risk Factors" therein, and other factors identified in Eos’s prior and future SEC filings with the SEC, available at www.sec.gov. ContactsInvestors: Ed Yuen, firstname.lastname@example.orgMedia: James McCusker, email@example.com
Footfall more than trebles as queues form outside branches of Primark, JD Sports and TK Maxx.
BUFFALO, N.Y. — The banged-up Boston Bruins are getting a boost for their late-season playoff push by acquiring forward Taylor Hall in a trade with the Buffalo Sabres reached early Monday. The Bruins also added checking line forward Curtis Lazar, who has missed the past six games with an upper body injury. Buffalo acquired fourth-year forward Anders Bjork and a second-round pick in a deal completed in advance of the NHL’s trade deadline. As part of the deal, the Sabres agreed to retain half of the remainder of Hall’s one-year, $8 million salary. The NHL’s 2018 MVP was deemed expendable by last-place Buffalo, which is already re-tooling for the future beyond this season. The Bruins have lost two straight following an 8-1 loss to the Washington Capitals on Sunday. At 21-12-6, they hold the East Division’s fourth and final playoff spot, and are four points ahead of the New York Rangers and Philadelphia Flyers. Boston has four players on injured reserve, including forward Ondrej Kase and defenceman Brandon Carlo. In the meantime, defencemen Charlie McAvoy missed his fourth game with an upper body injury, and defenceman Matt Grzelcyk is also sidelined. In a separate trade on Sunday, the Bruins also acquired defenceman Mike Reilly from the Ottawa Senators for a third-round pick. The Sabres, by comparison, continue to be in sell-off mode with the team all but mathematically assured of matching the NHL playoff drought record of 10 seasons. Buffalo traded defenceman Brandon Montour to Florida on Saturday, and previously traded veteran centre Eric Staal to Montreal. The Sabres began sitting out Hall for precautionary reasons since Tuesday in anticipation of him being dealt. Hall was the key to the trade because he was considered one of the few remaining impact forwards still on the market. Questions, however, have been raised as to whether his drop in production is the result of the 29-year-old having lost a step or because he’s playing on a struggling Sabres team which is 29th in goals-per-game. Hall, the No. 1 pick in the 2010 draft, was limited to two goals and 17 assists for 19 points in 37 games, and is in the midst of a 16-game goal drought. That’s a considerable drop from his 2017-18 MVP season in New Jersey, where he posted career-bests with 39 goals and 93 points in 76 games. Hall is on to his fourth team in two years. He was traded by New Jersey to Arizona last season, and then became a free agent after negotiations broke down with the Coyotes as a result of internal turmoil, which led Bill Armstrong taking over as general manager. Buffalo acquired the 24-year-old Bjork, who had two goals and three assists in 30 games this season, a year after generating a career-best nine goals and 19 points in 58 games. Overall, the 2014 fifth-round draft pick out of Notre Dame has 16 goals and 39 points in 138 career games with Boston. Very little has gone right for Buffalo. Coach Ralph Krueger was fired on March 17, and the Sabres' season was undone by mounting injuries and having to pause for two weeks following a COVID-19 outbreak in early February. Hall was among the most sought-after forwards on the free agent market in October, and surprised many by signing with Buffalo. He was reunited with Krueger, who played a key role in mentoring Hall during his first three seasons in Edmonton. Krueger pushed for the signing, making the case to management that Buffalo was one player away from being a contender despite coming off a season in which the team finished 13th in the Eastern Conference standings, and one spot from qualifying for the expanded playoffs. Hall was initially interested in staying in Buffalo on a long-term basis upon signing with the team. His focus began changing by eventually acknowledging he was open to waiving his no-trade clause last month while the team was in the midst of an 18-game winless skid — the NHL’s 14th longest. ___ More AP NHL: https://apnews.com/hub/NHL and https://twitter.com/AP_Sports John Wawrow, The Associated Press
Israel has not claimed responsibility for the attack. However, Israeli media reported that the country had orchestrated a devastating cyberattack that caused the blackout